Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) Return on Invested Capital (2017 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Return on Invested Capital for 9 consecutive years, with 0.34% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Invested Capital fell 35.0% year-over-year to 0.34%, compared with a TTM value of 0.34% through Dec 2025, down 35.0%, and an annual FY2025 reading of 0.4%, up 19.0% over the prior year.
  • Return on Invested Capital was 0.34% for Q4 2025 at Karyopharm Therapeutics, down from 0.43% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 4.49% in Q1 2023 and bottomed at 32.51% in Q1 2021.
  • Average Return on Invested Capital over 5 years is 0.53%, with a median of 0.92% recorded in 2021.
  • The sharpest move saw Return on Invested Capital plummeted -3092bps in 2021, then surged 3350bps in 2022.
  • Year by year, Return on Invested Capital stood at 0.96% in 2021, then surged by 90bps to 1.82% in 2022, then plummeted by -40bps to 1.1% in 2023, then tumbled by -37bps to 0.69% in 2024, then plummeted by -50bps to 0.34% in 2025.
  • Business Quant data shows Return on Invested Capital for KPTI at 0.34% in Q4 2025, 0.43% in Q3 2025, and 0.69% in Q4 2024.